Understanding Neurotoxicity After CAR T-Cell Therapy
This study aims to understand why some people experience neurotoxicity (problems with the brain and nervous system) after receiving chimeric antigen receptor (CAR) T-cell therapy for cancer. Researchers want to develop a new tool to identify early those patients who might develop immune effector cell-associated neurotoxicity syndrome (ICANS). If you are 18 or older, have signed an informed consent form, and are scheduled to receive commercial CAR T-cell therapy, you may be eligible. The study will involve brain magnetic resonance imaging (MRI), tests of your thinking and memory, quality of life questionnaires, and blood tests. The main goal is to see if a new tool can be developed to identify patients at risk for ICANS, with initial measurements taken at 2 weeks.
- Study design
- This is an observational study with 36 planned participants. It is a single-arm study, meaning all participants will receive the same evaluations.
- What's involved
- You would undergo brain MRI, neurocognitive assessments (tests of thinking and memory), and complete quality of life questionnaires. Blood samples will also be collected.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at 2 weeks, but the overall duration of follow-up is not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Neuroimaging and Biomarkers of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Kathryn Tringale, MD, MAS · PRINCIPAL_INVESTIGATOR · University of California, San Diego
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Principal component analysis (PCA)2 weeks
To identify relevant variables within three main domains (tumor imaging, neurocognitive assessments, and liquid biomarkers) collected acutely after chimeric antigen receptor (CAR) T-cell therapy that reflect distinct signatures associated with the presence of immune effector cell-associated neurotoxicity syndrome (ICANS).